/
Other
Staphylococcus Aureus
12
Pipeline Programs↗
14
Active Trials↗
23
Companies Involved↗
Staphylococcus Aureus is an emerging landscape with 12 programs across 23 companies. The most active players are AstraZeneca. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 11
Phase 21
Approved
No programs
Analysis
Trial Status
101
clinical trials
Completed68 · 67%
Recruiting10 · 10%
Terminated8 · 8%
Withdrawn6 · 6%
Unknown status4 · 4%
Active, not recruiting2 · 2%
Other3 · 3%
Clinical Trials
Trial Activity
101 trials
Study of the Nasal Intracellular Reservoir of Staphylococcus Aureus in Patients With S. Aureus Bacteremia
Recruiting·—·N/A·NCT06594250·405 enrolled
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia
Recruiting·—·Phase 3·NCT06336824·290 enrolled
Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia
Active, not recruiting·—·N/A·NCT07186894·5,000 enrolled
Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia
Not yet recruiting·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 2·NCT07384702·230 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)